How Chlamydia uses a protein to merge its compartments inside human cells
Regulation of homotypic fusion by Chlamydia
This project looks at whether a Chlamydia protein called IncA controls how the bacteria's internal compartments merge inside infected human cells, which could help people with Chlamydia infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11249572 on NIH RePORTER |
What this research studies
If you have or are at risk for Chlamydia, this work focuses on how the bacterium survives and spreads inside human cells. The team will use infected cell cultures and molecular tools to observe the bacterial inclusion, a membrane pocket where Chlamydia grows, and test different versions of the IncA protein to see how it controls merging of these pockets. They will combine cell biology, protein biochemistry, and microscopy to pinpoint the parts of IncA that turn fusion on or off. The goal is to map the steps Chlamydia needs to mature its inclusion and survive inside cells.
Who could benefit from this research
Good fit: People with active or recurrent Chlamydia infections or those willing to provide clinical samples (for example swabs or tissue specimens) would be the most relevant candidates for related sample-collection efforts.
Not a fit: People without Chlamydia or those seeking immediate new treatments are unlikely to get direct or immediate benefit from this basic laboratory research.
Why it matters
Potential benefit: If successful, the findings could reveal new targets for drugs or vaccines that block Chlamydia survival and reduce sexual-transmission disease and infection-related blindness.
How similar studies have performed: Previous work has shown IncA is required for inclusion fusion, but the detailed molecular regulation is largely untested, so this project builds on known findings with novel mechanistic experiments.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Paumet, Fabienne Michelle — Thomas Jefferson University
- Study coordinator: Paumet, Fabienne Michelle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.